Clinical Study
Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis
Table 1
Baseline characteristics of study patients.
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Values are mean standard deviation, unless otherwise noted. BMI: body mass index; mITT: modified Intent-To-Treat (patients completing both treatment periods). |